You are here: Industry Insights > VTX-801

News List

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease drugs
August 20, 2021
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy.
Vivet, Pfizer sign manufacturing pact for investigational gene therapy to treat Wilson disease expresspharma
September 24, 2020
Vivet Therapeutics and Pfizer announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801 ...
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics pharmafocusasia
March 21, 2019
Vivet Therapeutics, a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc.